Al-Tayyib A, Rice E, Rhoades H, Riggs P. Association between prescription drug misuse and injection among runaway homeless youth.
Drug Alcohol Depend. 2013; 134: 406-9. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/24300900 Accessed on: 2014-09-26.
Alford D, LaBelle C, Richardson J, O’Connell J, Hohl C, Cheng D, Samet J. Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based Setting.
Society of General Internal Medicine. 2007; 22: 171-176. Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1824722/ Accessed on: 2013-10-09.
Alford DP, Labelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.
Archives of Internal Medicine. 2011; 171(5): 425-31. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059544/ Accessed on: 2013-10-08.
Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
Drug Alcohol Depend. 2007; 88(1): 75-8. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/17055191 Accessed on: 2013-12-09.
Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
Am J Addict. 2004; 13 Suppl 1: S42-66. Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1255908/ Accessed on: 2013-10-09.
Arfken CL, Johanson CE, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.
J Subst Abuse Treat. 2010; 39(2): 96-104. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/20598829 Accessed on: 2013-10-08.
Babor T, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT: The Alcohol Use Disorders Identification Test: guidelines for use in primary care.
World Health Organization: Department of Mental Health and Substance Dependence. Second Edition. 2001. Available at:
http://www.talkingalcohol.com/files/pdfs/WHO_audit.pdf Accessed on: 2014-09-21.
Baca CT, Yahne CE. Smoking cessation during substance abuse treatment: what you need to know.
J Subst Abuse Treat. 2009; 36(2): 205-19. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/18715746 Accessed on: 2014-01-08.
Back SE , Payne RL , Simpson AN . Gender and prescription opioids: findings from the National Survey on Drug Use and Health.
Addict Behav. 2010; 35: 1001-7. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/20598809 Accessed on: 2015-04-23.
Bliesener N, Albrecht S, Schwager A, et al.. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence.
J Clin Endocrinol Metab. 2005; 90(1): 203. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/15483091 Accessed on: 2016-04-26.
Blueshift Research. Camurus and Indivior Set to Significantly Sway the Opioid Abuse Treatment Market . Blueshift Research Report. 2017. Accessed on: 2017-03-21.
Brady KT, Myrick H, Sonne S. Comorbid addiction and affective disorders.
In: Graham AW, Schultz TK, eds. Principles of Addiction Medicine, Second Edition. Chevy Chase, Md: American Society of Addiction Medicine. 1998. Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851027/ Accessed on: 2013-10-10.
Brands B, Blake J, Sproule B, et al. Prescription opioid abuse in patients presenting for methadone maintenance treatment.
Drug Alcohol Depend. 2004; 73(2): 199-207. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/14725960 Accessed on: 2014-01-08.
Brown RL, Leonard T, Saunders LA, Papasouliotis O. The prevalence and detection of substance use disorder among inpatients ages 18 to 49: an opportunity for prevention.
Preventive Medicine. 1998; 27: 101-110. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/9465360 Accessed on: 2013-10-08.
Bruce RD. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings.
International Journal of Drug Policy . 2010; 21: 122-124. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/19931444 Accessed on: 2015-04-23.
CDC. Understanding the epidemic.
Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Division of Unintentional Injury Prevention. 2017. Available at:
https://www.cdc.gov/drugoverdose/epidemic/index.html Accessed on: 2018-04-10.
Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003; 70(suppl 2): S39-S47.
Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy for chronic non-cancer pain.
J of Pain. 2009; 10(2): 113-130. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/19187889 Accessed on: 2013-10-08.
Christo PJ, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki DR, Jordan AE, Colson J. Urine Drug Testing In Chronic Pain.
Pain Physician . 2011; 14: 123-143. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/21412368 Accessed on: 2014-01-02.
Cicero JT, Dart RC, Inciardi JA, Woody GE, Schnoll S, Munoz A. The Development of a Comprehensive Risk-Management Program for Prescription Opioid Analgesics: Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS).
Pain Medicine. 2007; 8(2): 157-169. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/17305687 Accessed on: 2014-02-18.
Conigliaro J, Reyes CD, Parran TV, Schulz JE. Principles of screening and early intervention.
In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, eds. Principles of Addiction Medicine, Third Edition. Chevy Chase, Md: American Society of Addiction Medicine. 2003. Available at:
https://www.barnesandnoble.com/w/principles-of-addiction-medicine-american-society-american-society-of-addiction-medicine/1015772450?ean=9781880425084Accessed on: 2013-10-09.
Czerkes M. Buprenorphine Versus Methadone Treatment for Opiate Addiction in Pregnancy: An Evaluation of Neonatal Outcomes. American College of Obstetricians and Gynecologists Annual Clinical Meeting. 2010.
Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia.
Br J Anaesth. 2006; 96(5): 627-32. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/16547090 Accessed on: 2014-09-11.
Daitch D, Daitch J, Novinson D, et al. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. .
Pain Med. 2014; 15(12): 2087-94. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/25220043 Accessed on: 2016-06-04.
Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction. 2002; 97(11): 1383-1394.
Darnell B, Stieg RL. Boots on the Ground in Opioid Tapering: A Low-Cost, Medically Supervised Psychobehavioral Prescription Opioid Taper Program for Community-Dwelling Patients.
American Academy of Pain Medicine 2016 Annual Meeting. 2016. Available at:
http://www.painmed.org/2016posters/abstract-163/Accessed on: 2016-03-25.
Dart RC. Opioid Abuse, Misuse, and Diversion: Strategies for Prevention. Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS). American Academy of Pain Medicine Meeting. 2009. Accessed on: 2013-10-10.
Dasgupta N. RADARS System Subutex & Suboxone: How Much is Prescribed vs. Abuse/Diversion Reports.
SAMHSA Meeting on Buprenorphine. 2010. Available at:
http://www.buppractice.com/printpdf/425 Accessed on: 2013-04-30.
Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016.
MMWR Recomm Rep. 2016; ePub: March 2016: DOI: http://dx.doi.org/10.15585/mmwr.rr6501e1er. Available at:
http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm Accessed on: 2016-03-16.
Drugs.com. Doxazosin.
Drugs.com. Copyright 1996-2017 Cerner Multum, Inc. Version: 8.01.. Revision Date: 2015-11-16, 3:09:59 PM. Available at:
https://www.drugs.com/doxazosin.html Accessed on: 2017-01-03.
Dunn KE, Sigmon SC, Strain EC, et al.. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.
Drug Alcohol Depend. 2011; 119(1-2): 1-9. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/21741781 Accessed on: 2014-10-03.
Edlund MJ, Martin BC, Russo JE, et al.. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription.
Clin J Pain. 2014; 30(7): 557-64. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/24281273 Accessed on: 2014-10-07.
Egan JE, Casadonte P, Gartenmann T, Martin J, McCance-Katz EF, Netherland J, Renner JA, Weiss L, Saxon AJ, Fiellin DA. The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.
J Gen Intern Med. 2010; 25(9): 936-41. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917666/ Accessed on: 2013-10-09.
Erdemoglu AK, Koc R. Brief Pain Inventory score identifying and discriminating neuropathic and nociceptive pain..
Acta Neurol Scand. 2013; 128(5): 351-8. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/23594114 Accessed on: 2016-04-12.
Farmer CM, Lindsay D, Williams J, Ayers A, Schuster J, Cilia A, Flaherty MT, Mandell T, Gordon AJ, Stein BD. Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process. Substance Abuse Journal. 2015; 36(2): 209-216. Accessed on: 2015-10-06.
Farney RJ, McDonald AM, Boyle KM, Snow GL, Nuttall RT, Coudreaut MF, Wander TJ, Walker JM. Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone.
Eur Respir. 2013; 42: 394-403. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/23100497 Accessed on: 2014-01-27.
FDA. FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes .
FDA U.S. Food & Drug Administration. 3/22/2016. Available at:
http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm Accessed on: 2016-03-24.
Fiellin DA, Schottenfeld RS, Cutter CJ, et al. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial.
JAMA Internal Medicine. 2014; 174(12): 1947-1954. Available at:
http://archinte.jamanetwork.com/article.aspx?articleid=1916910 Accessed on: 2016-03-02.
Finch JW, Kamien JB, Amass L. Two-year experience with buprenorphine-naloxone (Suboxone) for maintenance treatment of opioid dependence within a private practice setting..
Journal of Addiction Medicine. 2014; 1(2): 104-110. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/21768942 Accessed on: 2016-03-02.
Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review.
Pain Medicine. 2008; 9(4): 444-459. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/18489635 Accessed on: 2013-10-09.
Fishman MJ, Mee-Lee D, Shulman GD, et al. Supplement to the ASAM Patient Placement Criteriaon the Management of Alcohol Use Disorders.
Baltimore, MD: Lippincott, Williams & Wilkins, Inc.. 2010. Available at:
http://www.asam.org/publications/the-asam-criteria Accessed on: 2013-12-14.
Fishman MJ, Wu LT, Woody GE. Buprenorphine for Prescription Opioid Addiction in a Patient With Depression and Alcohol Dependence .
Am J Psychiatry. 2011; 168(7): 675–679. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178807/ Accessed on: 2013-10-10.
Garra G, Singer AJ, Taira BR, et al. Validation of the Wong-Baker FACES pain rating scale in pediatric emergency department patients.
Academic Emergency Medicine. 2010; 17: 50-54. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/20003121 Accessed on: 2015-07-01.
Glasper A, Reed LJ, de Wet CJ, Gossop M, Bearn J. Induction of patients with moderately severe methadone dependence onto buprenorphine.
Addiction Biology. 2005; 10(2): 149-155. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/16191667 Accessed on: 2013-10-10.
Gourlay D, Heit H, Caplan Y. Urine Drug Testing in Primary Care: Dispelling the Myths & Designing Strategies.
California Academy of Family Physicians. 2002. Available at:
http://www.alaskaafp.org/udt.pdf Accessed on: 2005-03-15.
Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications..
Curr HIV/AIDS Rep. 2010; 7(3): 152-60. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/20532839 Accessed on: 2015-07-29.
Guo AY, Ma JD, Best BM, Atayee RS. Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine.
Journal of Analytical Toxicology. 2013; 37(9): 636-41. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/24080973 Accessed on: 2014-01-06.
Hagan H, Pouget ER, Des Jarlais DC. A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs.
The Journal of Infectious Diseases . 2011; 204: 74-83. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/21628661 Accessed on: 2015-04-23.
Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco.
Hepatology. 2001; 34(1): 180-187. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/11431749 Accessed on: 2013-10-10.
Hale, Viner. Trends in the prevalence of multiple substance use in adolescents in England, 1998-2009.
J of Public Health, Oxford. 2013; 35(3): 367-74. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/23528672 Accessed on: 2015-04-24.
Herve S, Riachi G, Noblet C, Guillement N, Tanasescu S, Odile G, Thuillez C, Tranvouez J, Ducrotte P, Lerebours E. Acute hepatitis due to buprenorphine administration.
European Journal of Gastroenterology and Hepatology. 2004; 16(10): 1033-1037. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/15371928Accessed on: 2013-10-08.
Hesse M. The ASRS-6 Has Two Latent Factors: Attention Deficit and Hyperactivity.
Journal of Attention Disorders. 2011; 17(3): 203–207. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/22262467 Accessed on: 2015-04-21.
Hopfer CJ, Khuri E, Crowley TJ, Hooks S. Adolescent heroin use: a review of the descriptive and treatment literature.
J Subst Abuse Treat. 2002; 23(3): 231-237. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/12392810 Accessed on: 2013-10-09.
Huestis MA. High-dose buprenorphine in humans.
In: Kintz P, Marquet P, eds. Buprenorphine Therapy of Opiate Addiction. Totowa, NJ: Humana Press, Inc. 2002. Available at:
http://www.amazon.com/dp/158829031X
Johanson CE, Arfken CL, DiMenza S, Schuster CR. Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians.
Drug and Alcohol Dependence. 2012; 120(1-30: 190-195. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/21862241 Accessed on: 2012-07-19.
Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O’Grady KE, Selby P, Martin PR, Fischer G. Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure.
New England Journal of Medicine. 2010; 363: 2320-2331. Available at:
http://www.nejm.org/doi/full/10.1056/NEJMoa1005359 Accessed on: 2013-10-09.
Jones HE. Treating opioid use disorders during pregnancy: historical, current, and future directions.
Subst Abus. 2013; 34(2): 89-91. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/23577898 Accessed on: 2014-02-05.
Joseph AM, Willenbring ML, Nugent SM, Nelson DB. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment.
J Stud Alcohol. 2004; 65(6): 681-91. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/15700504 Accessed on: 2014-01-08.
Jung O, Haack HS, Buettner M. Renal AA-amyloidosis in intravenous drug users – a role for HIV-infection?.
BMC Nephrology . 2012; 13: . Available at:
http://www.ncbi.nlm.nih.gov/pubmed/23171281 Accessed on: 2015-05-05.
Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.
Lancet. 2003; 361(9358): 662-8. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/12606177 Accessed on: 2013-10-09.
Kao MC, Zheng P, Mackey S, et al.. Trends in Benzodiazepine Prescription and Co-Prescription with Opioids in the United States, 2002––2009.
AAPM Annual Meeting. . Available at:
http://www.painmed.org/2014posters/abstract-109/ Accessed on: 2015-04-23.
Kidorf M, Disney ER, King VL, Neufeld K, Beilenson PL, Brooner RK. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program.
Drug Alcohol Depend. 2004; May 10; 74(2): 115-22. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/15099655 Accessed on: 2013-10-09.
Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a National Sample of Qualified Addiction Specialists Who Have and Have Not Prescribed Buprenorphine for Opioid Dependence.
Journal of Addictive Diseases. 2006; 25(4): 91-103. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/17088229 Accessed on: 2013-10-08.
Kleber H, Weiss R, Anton R, et al. Practice guideline for the treatment of patients with substance use disorders, 3rd edition.
American Psychiatric Association. 2010. Available at:
http://www.guideline.gov/content.aspx?id=24158 Accessed on: 2015-06-30.
Knight JR, Shrier LA, Bravender TD, Farrell M, Vander Bilt J, Shaffer HJ. A new brief screen for adolescent substance abuse.
Archives of Pediatric and Adolescent Medicine. 1999; 153(6): 591-596. Available at:
http://archpedi.ama-assn.org/cgi/reprint/153/6/591 Accessed on: 2011-07-14.
Krebs EE, Lorenz KA, Bair MJ. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference.
J Gen Intern Med. 2009; 24(6): 733-738. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686775/ Accessed on: 2016-04-26.
Labelle C, Han SC, Bergeron A, Samet JH. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
Journal of Substance Abuse Treatment. 2015; 15: . Available at:
https://www.ncbi.nlm.nih.gov/pubmed/26233698
Lavonas EJ, Banner W, Bradt P, Bucher-Bartelson B, Brown KR, Rajan P, Murrelle L, Dart RC, Green JL. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children.
Journal of Pediatrics. 2013; 163(5): 1377-83. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/23993129 Accessed on: 2014-01-06.
Lee JD, Friedmann PD, Kinlock TW, et al.. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders.
N Engl J Med. 2016; 374: 1232-1242. Available at:
http://www.nejm.org/doi/full/10.1056/NEJMoa1505409 Accessed on: 2016-04-27.
Lemon SC, Friedmann PD, Stein MD. The impact of smoking cessation on drug abuse treatment outcome.
Addict Behav. 2003; 28(7): 1323-31. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/12915172 Accessed on: 2014-01-08.
Levy S, Vaughan BL, Angulo M, Knight JR. Buprenorphine replacement therapy for adolescents with opioid dependence: early experience from a children’s hospital-based outpatient treatment program.
Journal of Adolescent Health. 2007; 40(5): 477-82. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/17448411 Accessed on: 2013-10-09.
Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, Rosenthal RN, Beebe KL. Buprenorphine Implants for Treatment of Opioid Dependence.
JAMA. 2010; 304(14): 1576-83. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/20940383 Accessed on: 2013-10-08.
Ling W, Hillhouse , Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R. Buprenorphine tapering schedule and illicit opioid use.
Addiction. 2009; 104(2): 256-65. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150159/ Accessed on: 2013-10-09.
Ling W. Prescription Drug Abuse. Presented at the Western Conference on Addiction, Universal City, CA, 11-13-05. 2005.
Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.
J Addict Med. 2014; 8(5): 315-26. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/25221984 Accessed on: 2014-10-03.
Lundahl B, Moleni T, Burke BL, et al. Motivational interviewing in medical care settings: a systematic review and meta-analysis of randomized controlled trials..
Patient Educ Couns. 2013; 93(2): 157-68. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/24001658 Accessed on: 2014-09-17.
Madras BK, Wilson MC, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and six months.
Drug Alcohol Depend. 2010; 99(1-3): 280-295. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760304/ Accessed on: 2013-10-09.
Manchikanti L, Manchukonda R, Damron KS. Does adherence monitoring reduce controlled substance abuse in chronic pain patients?.
Pain Physician. 2006; 9(1): 57-60. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/16700282 Accessed on: 2014-01-09.
Mannelli P, Peindl KS, Lee T. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.
Curr Drug Abuse Rev. 2012; 5(1): 52-63. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496559/ Accessed on: 2015-04-29.
Manubay JM, Muchow C, Sullivan MA. Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics.
Prim Care. 2011; 38(1): 71-90, vi. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328297/ Accessed on: 2013-10-10.
Martin J. Personal Communication re: number of patients maintained on buprenorphine. E-mail. 2011. Accessed on: 2011-03-31.
Martin T & Rocque M. Accidental and Non-Accidental Ingestion of Methadone and Buprenorphine in Childhood: A Single Center Experience, 1999-2009.
Current Drug Safety. 2009; 6: 12-16. Available at:
http://www.eurekaselect.com/73173/article Accessed on: 2013-12-05.
Martins SS, Keyes KM , Storr CL. Pathways between non-medical opioid use/dependence and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
Drug and Alcohol Dependence . 2009; 103: 16-24. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699563/Accessed on: 2015-04-24.
Matson SC, Hobson G, Abdel-Rasoul M, Bonny AE. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic. Addict Behav. 2014; 8(3): 176-82.
McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, Rainey PM. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.
Drug and Alcohol Dependence. Science Direct. 2007; 91(2-3): 269-78. Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272856/Accessed on: 2013-10-08.
McCance-Katz EF. Treatment of Opioid Dependence and Coinfection with HIV and Hepatitis C Virus in Opioid-Dependent Patients: The Importance of Drug Interactions between Opioids and Antiretroviral Agents.
Clin Infect Dis. 2005; 41(Suppl 1): S89-95. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/16265622Accessed on: 2013-10-08.
McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dose maintenance in pregnancy: maternal and neonatal outcomes.
American Journal of Obstetric Gynecology. 2005; 193(3 Pt 1): 606-10. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/16150249 Accessed on: 2013-10-09.
McNicholas LF. Buprenorphine: Induction, Dosing and Related Issues.
American Psychiatric Association Sponsored Webinar. 2011. Available at:
http://vimeo.com/20803777 Accessed on: 2013-10-08.
Mdege ND , Lang J. Screening instruments for detecting illicit drug use abuse that could be useful in general hospital wards: a systematic review .
Addictive Behaviors . 2011; 36: 1111-1119. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/21821364 Accessed on: 2015-04-23.
Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?.
Drug Alcohol Depend. 2003; 70(2S): S29-S37. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/12738348 Accessed on: 2013-10-08.
Minozzi S, Amato L, Davoli M. Maintenance treatments for opiate dependent adolescent .
Cochrane Database Syst Rev. 2009; 15(2): CD007210. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/19370679 Accessed on: 2013-10-09.
Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
Ann Fam Med. 2007; 5(2): 146-50. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1838690/ Accessed on: 2013-10-08.
Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O’Conner PG, Schottenfeld RS. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.
J Gen Intern Med. 2007; 22: 527-530. Available at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1829433/Accessed on: 2014-01-08.
Moos RH, Moos BS, Finney JW. Predictors of deterioration among patients with substance-use disorders.
J Clin Psychol. 2001; 57(12): 1403-1419. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/11745584 Accessed on: 2013-10-09.
Morasco BJ, Cavanagh R, Gritzner S , Dobscha SK. Care management practices for chronic pain in veterans prescribed high doses of opioid medications..
Farm Pract . 2013; 6: 671-8. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972371/ Accessed on: 2014-11-07.
Nasser AF, Heidbreder C, Liu Y, et al.. Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (Child-Pugh classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. .
Clinical Pharmacokinetics. 2015; 54(8): 837-49. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/25603822 Accessed on: 2016-03-03.
Neaigus A, Miller M, Gyarmathy VA, Friedman SR. HIV heterosexual sexual risk from injecting drug users among HIV-seronegative noninjecting heroin users.
Subst Use Misuse. 2011; 46(2-3): 208-17. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/21303241 Accessed on: 2013-10-10.
Nielsen S , Hillhouse M , Thomas C. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users.
J Addict Med . 2013; 7(1): 33-8. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/23222095 Accessed on: 2015-05-14.
Nielsen S, Dietze P, Lee N, Dunlop A, Taylor D. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment.
Addiction. 2007; 102(4): 616-22. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/17286641 Accessed on: 2014-02-07.
Nielsen S, Hillhouse M, Thomas C, Hasson A, Ling W. A Comparison of Buprenorphine Taper Outcomes Between Prescription Opioid and Heroin Users.
J Addict Med. 2013; 7: 33-8. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/23222095 Accessed on: 2014-01-08.
Oreskovich MR, Saxon AJ, Ellis ML, Malte CA, Reoux JP, Knox PC. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin.
Drug Alcohol Depend. 2005; 77(1): 71-9. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/15607843 Accessed on: 2013-10-09.
O’Connor AB, Collett A, Alto WA, O’Brien LM. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy .
Journal of Midwifery Women’s Health. 2013; 58(4): 383-8. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/23931660 Accessed on: 2014-06-18.
Pade PA, Cardon KE, Hoffman RM, Geppert CM. Prescription opioid abuse, chronic pain, and primary care: a Co-occurring Disorders Clinic in the chronic disease model.
J Subst Abuse Treat. 2012; 43(4): 446-50. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/22980449 Accessed on: 2014-10-07.
Pajusco B, Chiamulera C, Quaglio G, Moro L, Casari R, Amen G, Faccini M, Lugoboni F. Tobacco Addiction and Smoking Status in Heroin Addicts under Methadone vs. Buprenorphine Therapy.
Int J Environ Res Public Health. 2012; 9(3): 932–942. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367288/ Accessed on: 2014-01-08.
Passik S. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation.
Journal of Pain and Palliative Care Pharmacotherapy. 2006; 20(2): 5-13. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/16702131 Accessed on: 2013-10-10.
Patrick, D. Dual diagnosis: substance-related and psychiatric disorders. The Nursing Clinics of North America. 2003; 38: 67-73.
Pickett M, Rogers PD, Cavanaugh RM Jr. Screening for alcohol, tobacco, and drug use in children and adolescents.
In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, eds. Principles of Addiction Medicine, Third Edition. Chevy Chase, Md: American Society of Addiction Medicine. 2003. Available at:
https://www.barnesandnoble.com/w/principles-of-addiction-medicine-american-society-american-society-of-addiction-medicine/1015772450?ean=9781880425084Accessed on: 2013-10-08.
Potter JS, Marino En, Hillhouse MP. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
J Stud Alcohol Drugs. 2013; 74(4): 605-13. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/23739025 Accessed on: 2015-05-05.
Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery.
J Consult Clin Psychol. 2004; 72(6): 1144-56. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/15612860 Accessed on: 2014-01-08.
Purdue Pharma. Butrans™ CIII (buprenorphine) Transdermal System.
Butrans Website. 2010. Available at:
http://www.butrans.com/
Reid MS, Selzer J, Rotrosen J. Smoking Cessation treatment at Substance Abuse Rehabilitation Programs.
Northeast ATTC Newsletter. 2006; 5(2): 2-5. Available at:
http://ctndisseminationlibrary.org/PDF/156.pdf Accessed on: 2014-01-08.
Romano G, Barbera N, Spadaro G, Valenti V. Determination of drugs of abuse in hair: evaluation of external heroin contamination and risk of false positives.
Forensic Sci Int. 2003; 131(2-3): 98-102. Available at:
http://www.sciencedirect.com/science/journal/03790738 Accessed on: 2013-10-10.
Rondinelli AJ, Ouellet LJ, Strathdee SA, Latka MH, Hudson SM, Garfein RS. Young adult injection drug users in the United States continue to practice HIV risk behaviors.
Drug Alcohol Depend. 2009; 104(1-2): 167-74. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/19559543 Accessed on: 2014-02-18.
Rosenthal RN, Lofwall MR, Kim S, et al. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine. A randomized clinical trial.
JAMA. 2016; 316: 282-290. Available at:
http://jama.jamanetwork.com/article.aspx?articleid=2533504Accessed on: 2016-07-25.
Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence.
Am J Drug Alcohol Abuse. 2011; 37(1): 1-11. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/21247284 Accessed on: 2013-10-10.
Salsitz EA, Wunsch MJ. PCSS-B Guidance on Drug Enforcement Administration Requirements for Prescribers and Dispensers of Buprenorphine and Buprenorphine/Naloxone.
American Academy of Addiction Psychiatry. 2010; January 25: . Available at:
https://www.naabt.org/documents/PCSS_All-Guidance-06022010.pdf Accessed on: 2013-12-10.
SAMHSA. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. TIP 40.
SAMHSA/CSAT. Treatment Improvement Protocols. 2004; TIP 40: . Available at:
https://www.ncbi.nlm.nih.gov/books/NBK64245/ Accessed on: 2016-10-25.
Savage SD, Kirsh KL, Passik, SD. Challenges in using opioids to treat pain in persons with substance use disorders.
Addiction Science & Clinical Practice. 2008. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/18497713 Accessed on: 2011-04-15.
Senay EC. Opioids: methadone maintenance. In: Galanter M, Kleber HD, eds. Textbook of Substance Abuse Treatment. 2nd ed. Washington, DC: American Psychiatric Press, Inc. 1999.
Shoptaw S, Rotheram-Fuller E, Yang X, Frosch D, Nahom D, Jarvik ME, Rawson RA, Ling W. Smoking cessation in methadone maintenance.
Addiction. 2002; 97(10): 1317-28. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/12359036 Accessed on: 2014-01-08.
Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care.
Archives of Internal Medicine. 2010; 170(13): 1155-60. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911954/ Accessed on: 2013-10-08.
Stanhope TJ, Gill LA, Rose C. Chronic opioid use during pregnancy: maternal and fetal implications.
Clinics in Perinatology. 2013; 40(3): 337-50. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/23972743 Accessed on: 2014-06-18.
Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD).
Cochrane Database Systematic Reviews . 2006; 1: . Available at:
http://www.ncbi.nlm.nih.gov/pubmed/16437445 Accessed on: 2015-09-01.
Sterling S, Chi F, Hinman A. Integrating Care for People With Co-Occurring Alcohol and Other Drug, Medical, and Mental Health Conditions .
Alcohol Research & Health. 2011; 33(4): 338-349. Available at:
http://pubs.niaaa.nih.gov/publications/arh334/338-349.pdf Accessed on: 2014-01-07.
Stewart DG, Brown SA. Withdrawal and dependency symptoms among adolescent alcohol and drug abusers.
Addiction. 1995; 90(5): 627-635. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/7795499 Accessed on: 2013-10-09.
Strain EC, Moody DE, Stoller KE, Walsh SL, Bigelow GE. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.
Drug and Alcohol Dependence. 2004; 74(1): 37-43. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/15072805 Accessed on: 2013-10-08.
Strain EC. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain. 2002; 18(4 Suppl): S14-27.
Subramaniam GA, Fishman MJ, Woody G. Treatment of opioid-dependent adolescents and young adults with buprenorphine.
Current Psychiatry Reports. 2009; 11(5): 360-3. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/19785976 Accessed on: 2013-10-09.
Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT). A Guide to Substance Abuse Services for Primary Care Clinicians.
Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration. 2008. Available at:
https://www.ncbi.nlm.nih.gov/books/NBK64827/ Accessed on: 2013-10-08.
Substance Abuse and Mental Health Services Administration (SAMHSA). Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction.
Rockville, Md: Center For Substance Abuse Treatment. Treatment Improvement Protocol Series, No. 40, USDHHS Publication (SMA) 04-3939. 2004b. Available at:
https://www.ncbi.nlm.nih.gov/books/NBK64245/ Accessed on: 2013-10-08.
Substance Abuse and Mental Health Services Administration (SAMHSA). Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence: A Curriculum for Physicians.
Substance Abuse and Mental Health Services Administration. 2001. Available at:
http://www.uiphp.org.ua/media/1488 Accessed on: 2013-10-08.
Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. Intensive Outpatient Treatment for Alcohol and Other Drug Abuse.
Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration. Technical Improvement Protocol Series, No. 8. 1993b. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/22514865 Accessed on: 2013-10-09.
Substance Abuse and Mental Health Services Administration. Treatment of Adolescents With Substance Use Disorders.
Treatment Improvement Protocol Series, No. 32. Rockville, Md: Center For Substance Abuse Treatment. USDHHS Publication (SMA) 99-3283. 1999. Available at:
https://www.ncbi.nlm.nih.gov/books/NBK64350/ Accessed on: 2013-10-09.
Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).
Br J Addict. 1989; 84(11): 1353-7. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/2597811 Accessed on: 2017-03-16.
Tamm L, Trello-Rishel K, Riggs P, Nakonezny P, Acosta M, Bailey G, Winhusen T. Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder.
Subst Abuse Treat. 2013; 44(2): 224-30. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499678/Accessed on: 2014-09-26.
Taylor FB, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: A placebo-controlled study.
Biological Psychiatry. 2008; 63(6): 629-32. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/17868655 Accessed on: 2015-09-01.
Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Medication-assisted treatment with buprenorphine: assessing the evidence.
Psychiatr Serv. 2014; 65(2): 158-70. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/24247147 Accessed on: 2014-06-18.
TransMed. CLIA Screen In-Vitro (CSI) 12-Panel Drug Test Screening Cup CLIA Waived.
TransMed Drug Testing & Laboratory Supplies. . Available at:
http://www.transmedco.com/CLIA/CSI-12.html Accessed on: 2016-08-10.
Trémeau F, Darreye A, Staner L, Corrêa H, Weibel H, Khidichian F, Macher JP. Suicidality in opioid-dependent subjects.
Am J Addict. 2008; 17(3): 187-94. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/18463995 Accessed on: 2013-10-10.
Tzschentke TM. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction.
Psychopharmacology (Berl). 2002; 161(1): 1-16. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/11967625 Accessed on: 2013-10-08.
U.S. Drug Enforcement Administration (DEA), Office of Diversion Control. National Forensic Laboratory Information System: Year 2009 Annual Report.
National Forensic Library Information System Annual Report. 2010. Available at:
http://www.deadiversion.usdoj.gov/nflis/2009annual_rpt.pdf Accessed on: 2011-04-14.
USDHHS. Facing Addiction in America. The Surgeon General’s Report on Alcohol, Drugs, and Health.
Surgeon General Reports. 2016. Available at:
https://addiction.surgeongeneral.gov/ Accessed on: 2016-11-17.
Walsh SL. Clinically Relevant Pharmacology of Buprenorphine.
UK HealthCare CECentral. 2009. Available at:
http://www.cecentral.com/ Accessed on: 2011-07-18.
Wang J, Christo PJ. The influence of prescription monitoring programs on chronic pain management.
Pain Physician. 2009; 12: 507-515. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/19461820 Accessed on: 2014-05-24.
Warden D, Riggs P, Min S, Mikulich-Gilbertson S, Tamm L, Trello-Rishel K, Winhusen T. Major depression and treatment response in adolescents with ADHD and substance use disorder.
Drug Alcohol Depend. 2012; 120(1-3): 214-9. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245790/ Accessed on: 2014-09-26.
Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006.
National Center for Health Statistics Data Brief. 2009; NCHS Data Brief, no. 22: . Available at:
http://www.cdc.gov/nchs/data/databriefs/db22.pdf Accessed on: 2011-04-15.
Wartenberg A. Management of Buprenorphine Side Effects.
American Psychiatric Association. 2013. Available at:
http://www.psychiatry.org/home Accessed on: 2013-12-12.
Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson HL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W. Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence.
Arch Gen Psychiatry. 2012; 68(12): 1238-1246. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470422/ Accessed on: 2014-01-08.
Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM, McDermott KA, Srisarajivakul EN, Dodd DR, Dreifuss JA, McHugh RK, Carroll KM. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study.
Drug and Alcohol Dependence. 2015. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/25818060 Accessed on: 2015-12-04.
Wish ED, Artigiani D, Billing A, Hauser W, et al. The emerging buprenorphine epidemic in the United States.
J Addict Dis. 2012; 31(1): 3-7. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/22356664 Accessed on: 2012-07-19.
Woody G, Poole S, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trail.
AMA. 2008; 300(17): 2003-11. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2610690/ Accessed on: 2014-09-26.
Wu LT, Woody GE, Yang C, Blazer DG. Subtypes of nonmedical opioid users: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
Drug Alcohol Depend. 2010; 112: 69–80. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967592/ Accessed on: 2015-04-15.
Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.
Curr Drug Abuse Rev. 2011; 4: 28-41. Available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154701/ Accessed on: 2013-12-05.
Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C. College on Problems of Drug Dependence task force on prescription opioid non-medical use and abuse: position statement.
Drug Alcohol Depend. 2003; 69(3): 215-232. Available at:
https://www.ncbi.nlm.nih.gov/pubmed/12633908 Accessed on: 2013-10-09.
Zubkoff L, Shiner B, Watts BV. Staff Perceptions of Substance Use Disorder Treatment in VA Primary Care–Mental Health Integrated Clinics.
Journal of Substance Abuse Treatment. 2016; 70: 44-49. Available at:
http://dx.doi.org/10.1016/j.jsat.2016.07.011 Accessed on: 2016-12-02.
Öhlin L, Fridell M, Nyhlén A. Buprenorphine maintenance program with contracted work/education and low tolerance for non-prescribed drug use: a cohort study of outcome for women and men after seven years.
BMC Psychiatry. 2015; 15:56 (ISSN: 1471-244X). 2015; 15(56): ISSN: 1471-244X. Available at:
http://www.biomedcentral.com/1471-244X/15/56 Accessed on: 2015-09-17.